86831-53-0
Chemical Structure
Rhodiolin
- CAS No.: 86831-53-0
- Formula:C25H20O10
- Molecular Weight:480.42
IUPAC Name: (2R,3R)-6,8-dihydroxy-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-9-(4-hydroxyphenyl)-2,3-dihydro-7H-[1,4]dioxino[2,3-h]chromen-7-one
InChIKey: POVCYOFRCMBMKD-XMSQKQJNSA-N
SMILES: O=C1C2=C(O)C=C(O[C@H](C3=CC(OC)=C(O)C=C3)[C@@H](CO)O4)C4=C2OC(C5=CC=C(O)C=C5)=C1O
Biological Activity: Rhodiolin, a flavonoid, is an orally active glucose 6-phosphate isomerase (GPI) inhibitor. Rhodiolin inhibits papillary thyroid cancer (PTC) by targeting glycolysis enzyme glucose 6-phosphate isomerase GPI and suppressing PI3K/AKT/mTOR phosphorylation and induce apoptosis. Rhodiolin as a NS2B-NS3 protease inhibitor can disrupt dengue viral replication. Rhodiolin is also a potential candidate for developing anticancer strategies inhibiting CK1ε kinase. Rhodiolin can be used for the study of anti-tumor and anti-viral [1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rhodiolin | 98% | Rhodiolin, a flavonoid, is an orally active glucose 6-phosphate isomerase (GPI) inhibitor. Rhodiolin inhibits papillary thyroid cancer (PTC) by targeting glycolysis enzyme glucose 6-phosphate isomerase GPI and suppressing PI3K/AKT/mTOR phosphorylation and induce apoptosis. Rhodiolin as a NS2B-NS3 protease inhibitor can disrupt dengue viral replication. Rhodiolin is also a potential candidate for developing anticancer strategies inhibiting CK1ε kinase. Rhodiolin can be used for the study of anti-tumor and anti-viral . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bo J, et al. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. Phytomedicine. 2024 Sep;132:155804. [Content Brief]
- [2]. Hakami MA, et al. Identification of potential casein kinase I isoform epsilon inhibitors from phytoconstituents: implications for targeted anticancer therapeutics. J Biomol Struct Dyn. 2025 Apr 29:1-13. [Content Brief]
- [3]. Purohit P, et al. Targeting the DENV NS2B-NS3 protease with active antiviral phytocompounds: structure-based virtual screening, molecular docking and molecular dynamics simulation studies. J Mol Model. 2022 Oct 24;28(11):365. [Content Brief]
Keywords
